Conditions: Glioma
Keywords: relapsed lapatinib Pazopanib glioblastoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 75
Healthy volunteers: no

Brief summary:
This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.

Detailed description:
This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.

Arms:
arm 1: Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.

Interventions: intervention 1: pazopanib intervention 2: lapatinib
Intervention descriptions: intervention 1: Pazopanib is a novel compound being developed for the treatment of various cancers. intervention 2: Lapatinib is a novel compound being developed for the treatment of various cancers.

Protocol document: